Changes in HIV plasma viral load and lymphocyte subsets after chemotherapy for study group of 68 patients who survived more than 3 months after completing chemotherapy (chemo)
| . | First year following chemo . | Second year following chemo . | ||||||
|---|---|---|---|---|---|---|---|---|
| Median value at start of chemo (IQR) . | Median value at end of chemo (IQR) . | Median change from end of chemo at 1 mo after chemo (IQR) . | Median change from end of chemo at 3 mo after chemo (IQR) . | Median change from end of chemo at 6 mo after chemo (IQR) . | Median change from end of chemo at 12 mo after chemo (IQR) . | Median change from 12 mo to 18 mo after chemo (IQR) . | Median change from 12 mo to 24 mo after chemo (IQR) . | |
| Subjects, no. | 68 | 68 | 68 | 68 | 64 | 54 | 47 | 43 |
| CD4 cell count, per mL | 178 (66 to 269) | 127 (66 to 269) | +15.5 (−8.5-+97); P = .001 | +47 (+13-+122); P < .001 | +69 (+14-+134); P < .001 | +97 (+54-+193); P < .001 | +33 (−27-+81); P = .030 | +48 (+3-+128); P < .001 |
| CD8 cell count, per mL | 693 (462 to 984) | 440 (66 to 269) | +130 (−30-+404); P < .001 | +279 (+77-+565); P < .001 | +243 (+77-+446); P < .001 | +318 (+110-+562); P < .001 | −21 (−188-+221); P = .85 | +14 (−160-+244); P = .32 |
| CD19 cell count, per mL | 95 (47 to 170) | 3 (66 to 269) | +3.5 (0-+33); P < .001 | +80 (+38-+126); P < .001 | +102 (+56-+155); P < .001 | +137 (+85-+256); P < .001 | +10 (−32-+66); P = .055 | +34 (−11-+93); P = .004 |
| CD56 cell count, per mL | 59 (29 to 116) | 43 (66 to 269) | +4 (−6-+33); P = .066 | +7 (−8-+39); P = .005 | +15 (−8-+60); P < .001 | +32 (−3-+89); P < .001 | −4 (−25-+25); P = .94 | +12 (−36-+4); P = .89 |
| . | First year following chemo . | Second year following chemo . | ||||||
|---|---|---|---|---|---|---|---|---|
| Median value at start of chemo (IQR) . | Median value at end of chemo (IQR) . | Median change from end of chemo at 1 mo after chemo (IQR) . | Median change from end of chemo at 3 mo after chemo (IQR) . | Median change from end of chemo at 6 mo after chemo (IQR) . | Median change from end of chemo at 12 mo after chemo (IQR) . | Median change from 12 mo to 18 mo after chemo (IQR) . | Median change from 12 mo to 24 mo after chemo (IQR) . | |
| Subjects, no. | 68 | 68 | 68 | 68 | 64 | 54 | 47 | 43 |
| CD4 cell count, per mL | 178 (66 to 269) | 127 (66 to 269) | +15.5 (−8.5-+97); P = .001 | +47 (+13-+122); P < .001 | +69 (+14-+134); P < .001 | +97 (+54-+193); P < .001 | +33 (−27-+81); P = .030 | +48 (+3-+128); P < .001 |
| CD8 cell count, per mL | 693 (462 to 984) | 440 (66 to 269) | +130 (−30-+404); P < .001 | +279 (+77-+565); P < .001 | +243 (+77-+446); P < .001 | +318 (+110-+562); P < .001 | −21 (−188-+221); P = .85 | +14 (−160-+244); P = .32 |
| CD19 cell count, per mL | 95 (47 to 170) | 3 (66 to 269) | +3.5 (0-+33); P < .001 | +80 (+38-+126); P < .001 | +102 (+56-+155); P < .001 | +137 (+85-+256); P < .001 | +10 (−32-+66); P = .055 | +34 (−11-+93); P = .004 |
| CD56 cell count, per mL | 59 (29 to 116) | 43 (66 to 269) | +4 (−6-+33); P = .066 | +7 (−8-+39); P = .005 | +15 (−8-+60); P < .001 | +32 (−3-+89); P < .001 | −4 (−25-+25); P = .94 | +12 (−36-+4); P = .89 |
Percentage HIV VL less than 50 copies/mL was 31% at the start of chemotherapy; 69% at the end of chemotherapy; 75% at 1 month after chemotherapy; 79% at 3 months after chemotherapy; 81% at 6 months after chemotherapy; 87% at 12 months after chemotherapy; 87% at 18 months after chemotherapy; and 90% at 24 months after chemotherapy.